We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Sanofi | BIT:SANF | Italy | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.00 | - |
Sanofi Delivers Solid Sales and Business EPS Growth at CER Amidst Successful Product Launches and Advancements in Immunology Pipeline
Paris, February 1, 2024
Q4 2023 sales growth of 9.3% at CER and business EPS(1) increase of 8.2% at CER
Full-year 2023 delivered 5.3% sales growth and 5.4% business EPS growth at CER
R&D transformation and Key milestones in Q4
Progress on Corporate Social Responsibility strategy in Q4
Full-year 2024 business EPS guidance
Paul Hudson, Sanofi Chief Executive Officer, commented:
“2023 marked a critical year on our journey to become a development-driven, tech-powered biopharma company committed to serving patients and accelerating growth. We have delivered another year of strong underlying performance of our core drivers in Specialty Care and Vaccines supported by the outstanding launch execution of Beyfortus, Altuviiio and Tzield. With scientific news flow at an all-time high, pipeline advances and 12 potential blockbusters in late-stage development including amlitelimab, frexalimab and tolebrutinib, our R&D transformation has reached an inflection point on the road to industry leadership in immunology. Looking forward, we remain committed to investing in R&D to fully unlock the value of our pipeline, powered by AI at scale, and continue to focus on our expected launch opportunities such as Dupixent in COPD. At the same time, we are taking steps to become a pure-play biopharma company with more than €10bn sales contribution from Pharma launches by 2030(4).”
Q4 2023 | Change | Change at CER | 2023 | Change | Change at CER | |
IFRS net sales reported | €10,919m | +1.8% | +9.3% | €43,070m | +0.2% | +5.3% |
IFRS net income reported | -€555m | -117.8% | _ | €5,400m | -35.5% | — |
IFRS EPS reported | -€0.44 | -117.7% | _ | €4.31 | -35.6% | — |
Free cash flow(3) | €3,496m | +37.3% | _ | €8,478m | -0.1% | — |
Business operating income | €2,583m | -5.2% | +5.3% | €12,670m | -2.8% | +4.3% |
Business net income(1) | €2,083m | -2.7% | +8.2% | €10,155m | -1.8% | +5.5% |
Business EPS(1) | €1.66 | -2.9% | +8.2% | €8.11 | -1.8% | +5.4% |
Changes in net sales are expressed at constant exchange rates (CER) unless otherwise indicated (definition in Appendix 9). (1) In order to facilitate an understanding of operational performance, Sanofi comments on the business net income statement. Business net income is a non-IFRS financial measure (definition in Appendix 9). The consolidated income statement for Q4 2023 is provided in Appendix 3 and a reconciliation of reported IFRS net income to business net income is set forth in Appendix 4; (2) 2023 business EPS was €8.11; (3) Free cash flow is a non-IFRS financial measure (definition in Appendix 9). (4) Risk-adjusted net sales at CER . Already launched: ALTUVIIIO, TZIELD, Sarclisa, Nexviazyme, Rezurock, Xenpozyme, Enjaymo, Cablivi; Potential launches tolebrutinib, itepekimab, amlitelimab, frexalimab, rilzabrutinib, lunsekimig, Oral TNFR1si
Attachment
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions